$384 Million is the total value of Tamarack Advisers, LP's 32 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 108.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTIequity | $46,391,000 | +1.5% | 4,225,000 | +7.6% | 12.09% | -13.1% |
| BIO | Buy | BIO-RAD LABORATORIES-Aequity | $38,265,000 | +23.7% | 115,000 | +15.0% | 9.97% | +6.0% |
| PCRX | Buy | PACIRA BIOSCIENCES INCequity | $29,504,000 | +9.1% | 775,000 | +24.0% | 7.69% | -6.5% |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INCequity | $26,820,000 | +86.0% | 1,000,000 | +80.2% | 6.99% | +59.4% |
| ZBH | Buy | ZIMMER BIOMET HOLDINGS INCequity | $21,963,000 | +102.2% | 160,000 | +77.8% | 5.72% | +73.3% |
| ATRC | Buy | ATRICURE INCequity | $21,199,000 | +0.0% | 850,000 | +25.9% | 5.52% | -14.3% |
| LNTH | Buy | LANTHEUS HOLDINGS INCequity | $18,799,000 | -6.5% | 750,000 | +2.7% | 4.90% | -19.9% |
| HOLX | Buy | HOLOGIC INCequity | $14,137,000 | +8.6% | 280,000 | +1.8% | 3.68% | -6.9% |
| CMD | Buy | CANTEL MEDICAL CORPequity | $10,098,000 | +10.8% | 135,000 | +17.4% | 2.63% | -5.1% |
| CORV | Buy | CORREVIO PHARMA CORPequity | $9,000,000 | +21.0% | 4,500,000 | +34.3% | 2.34% | +3.7% |
| ITGR | New | INTEGER HOLDINGS CORPequity | $8,689,000 | – | 115,000 | +100.0% | 2.26% | – |
| HMSY | New | HMS HOLDINGS CORPequity | $7,755,000 | – | 225,000 | +100.0% | 2.02% | – |
| UTHR | New | UNITED THERAPEUTICS CORPequity | $5,981,000 | – | 75,000 | +100.0% | 1.56% | – |
| ICUI | New | ICU MEDICAL INCequity | $5,586,000 | – | 35,000 | +100.0% | 1.46% | – |
| PHR | New | PHREESIA INCequity | $4,848,000 | – | 200,000 | +100.0% | 1.26% | – |
| OPTN | New | OPTINOSE INCequity | $4,725,000 | – | 675,000 | +100.0% | 1.23% | – |
| RDNT | New | RADNET INCequity | $4,667,000 | – | 325,000 | +100.0% | 1.22% | – |
| NVRO | Buy | NEVRO CORPequity | $4,545,000 | +44.1% | 52,864 | +5.7% | 1.18% | +23.5% |
| GWPH | New | GW PHARMACEUTICALS -ADRdepository receipt | $2,876,000 | – | 25,000 | +100.0% | 0.75% | – |
| Buy | SPY US 10/18/19 P290put | $850,000 | +222.0% | 5,000 | +25.0% | 0.22% | +176.2% | |
| New | XLV US 10/18/19 P90put | $540,000 | – | 5,000 | +100.0% | 0.14% | – | |
| New | ABT US 10/18/19 P85put | $233,000 | – | 900 | +100.0% | 0.06% | – | |
| New | MDRX US 10/18/19 C10call | $208,000 | – | 2,000 | +100.0% | 0.05% | – | |
| New | MEDP US 12/20/19 P75put | $116,000 | – | 350 | +100.0% | 0.03% | – | |
| New | IWM US 10/18/19 C160call | $110,000 | – | 10,000 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-05
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.